



Skyrizi

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: _____ **Date:** _____

Patient's ID: _____ **Patient's Date of Birth:** _____

Physician's Name: _____

Specialty: _____ **NPI#:** _____

Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: Same as Requesting Provider

Name: _____ **NPI#:** _____

Fax: _____ **Phone:** _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider

Name: _____ **NPI#:** _____

Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ kg

Patient Height: _____ cm

Please indicate the place of service for the requested drug:

Ambulatory Surgical (POS Code 24)

Home (POS Code 12)

Off Campus Outpatient Hospital (POS Code 19)

On Campus Outpatient Hospital (POS Code 22)

Office (POS Code 11)

Drug Information:

Strength/Measure _____ *Units* ml Gm mg ea Un

Directions(sig) _____ *Route of administration* _____

Dosing frequency _____

What is the ICD-10 code? _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A - 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org.**



Criteria Questions:

1. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic drug (e.g., Olumiant, Otezla, Xeljanz)?
 Yes, *Continue to 2*
 No, *Continue to 2*

2. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic drug (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis?
 Yes, *Continue to 6*
 No, *Continue to 3*

3. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy?
 Yes, *Continue to 4*
 No, *Continue to 4*

4. What were the results of the TB test?
 Positive for TB, *Continue to 5*
 Negative for TB, *Continue to 6*
 Unknown, *No further questions*

5. Which of the following applies to the patient?
 Patient has latent TB and treatment for latent TB has been initiated, *Continue to 6*
 Patient has latent TB and treatment for latent TB has been completed, *Continue to 6*
 Patient has latent TB and treatment for latent TB has not been initiated, *Continue to 6*
 Patient has active TB, *Continue to 6*

6. What is the diagnosis?
 Plaque psoriasis, *Continue to 8*
 Psoriatic arthritis WITH co-existent plaque psoriasis, *Continue to 7*
 Psoriatic arthritis, *Continue to 22*
 Crohn's disease, *Continue to 37*
 Other, please specify. _____, *No further questions*

7. What is the primary diagnosis being treated?
 Psoriatic arthritis, *Continue to 22*
 Plaque psoriasis, *Continue to 8*

8. Has the patient been diagnosed with moderate to severe plaque psoriasis?
 Yes, *Continue to 9*
 No, *Continue to 9*

9. Is the patient an adult (18 years of age or older)?

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org**



- Yes, *Continue to 10*
- No, *Continue to 10*

10. Is the requested drug being prescribed by or in consultation with a dermatologist?

- Yes, *Continue to 11*
- No, *Continue to 11*

11. Is this request for continuation of therapy with the requested drug?

- Yes, *Continue to 12*
- No, *Continue to 16*

12. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

- Yes, *Continue to 16*
- No, *Continue to 13*
- Unknown, *Continue to 16*

13. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *Continue to 14*
- No, *Continue to 14*

14. Has the patient experienced a reduction in body surface area (BSA) affected from baseline? **ACTION REQUIRED:** If Yes, please attach chart notes or medical record documentation of decreased body surface area affected.

- Yes, *Continue to 44*
- No, *Continue to 15*

15. Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)? **ACTION REQUIRED:** If Yes, please attach chart notes or medical record documentation of improvement in signs and symptoms.

- Yes, *Continue to 44*
- No, *Continue to 44*

16. Has the patient ever received or is currently receiving a biologic (e.g., Humira) or targeted synthetic drug (e.g., Sotyktu, Otezla) indicated for the treatment of moderate to severe plaque psoriasis (excluding receiving the drug via samples or a manufacturer's patient assistance program)? **ACTION REQUIRED:** If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried.

- Yes, *Continue to 44*
- No, *Continue to 17*

17. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected? **ACTION REQUIRED:** If Yes, please attach chart notes or medical record documentation of affected areas.

- Yes, *Continue to 44*
- No, *Continue to 18*

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



18. What is the percentage of body surface area (BSA) affected (prior to starting the requested medication)? Indicate percentage. **ACTION REQUIRED:** Please attach chart notes or medical record documentation of body surface area affected.

Greater than or equal to 3% to less than 10% of BSA _____ % **ACTION REQUIRED:** Submit supporting documentation, Continue to 19

Greater than or equal to 10% of BSA _____ % **ACTION REQUIRED:** Submit supporting documentation, Continue to 44

Less than 3% of BSA _____ %, No further questions

19. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin? **ACTION REQUIRED:** If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.

Yes, Continue to 44

No, Continue to 20

20. Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin? **ACTION REQUIRED:** If Yes, please attach documentation of clinical reason to avoid therapy.

Yes, Continue to 21

No, Continue to 21

21. Please indicate the clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin.

Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease, Continue to 44

Drug interaction, Continue to 44

Risk of treatment-related toxicity, Continue to 44

Pregnancy or currently planning pregnancy, Continue to 44

Breastfeeding, Continue to 44

Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), Continue to 44

Hypersensitivity, Continue to 44

History of intolerance or adverse event, Continue to 44

Other, please specify. _____, Continue to 44

22. Is the patient an adult (18 years of age or older)?

Yes, Continue to 23

No, Continue to 23

23. Is the requested drug being prescribed by or in consultation with a rheumatologist or dermatologist?

Yes, Continue to 24

No, Continue to 24

24. Is this request for continuation of therapy with the requested drug?

Yes, Continue to 25

No, Continue to 28

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org.**



25. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

- Yes, *Continue to 28*
- No, *Continue to 26*
- Unknown, *Continue to 28*

26. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *Continue to 27*
- No, *Continue to 27*

27. Which of the following has the patient experienced an improvement in from baseline? **ACTION REQUIRED:** Please attach chart notes or medical record documentation supporting positive clinical response.

- Number of swollen joints **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Number of tender joints **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Dactylitis **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Enthesitis **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Axial disease **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Skin and/or nail involvement **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- None of the above, *Continue to 44*

28. Has the patient been diagnosed with active psoriatic arthritis (PsA)?

- Yes, *Continue to 29*
- No, *Continue to 29*

29. Has the patient ever received or is currently receiving a biologic (e.g., Humira) or targeted synthetic drug (e.g., Rinvoq, Otezla) that is indicated for the treatment of active psoriatic arthritis (excluding receiving the drug via samples or a manufacturer's patient assistance program)? **ACTION REQUIRED:** If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried.

- Yes, *Continue to 44*
- No, *Continue to 30*

30. What is the patient's disease severity?

- Mild to moderate, *Continue to 31*
- Severe, *Continue to 44*

31. Does the patient have enthesitis or predominantly axial disease?

- Yes, *Continue to 44*
- No, *Continue to 32*

32. Has the patient had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine) administered at an adequate dose and duration? **ACTION REQUIRED:** If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org**



- Yes, *Continue to 44*
- No, *Continue to 33*

33. Has the patient had an intolerance to methotrexate, leflunomide, or another conventional synthetic drug (e.g., sulfasalazine)? **ACTION REQUIRED:** If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.

- Yes, *Continue to 44*
- No, *Continue to 34*

34. Does the patient have a contraindication to methotrexate or leflunomide? **ACTION REQUIRED:** If Yes, please attach documentation of clinical reason to avoid therapy.

- Yes, *Continue to 36*
- No, *Continue to 35*

35. Does the patient have a contraindication to another conventional synthetic drug (e.g., sulfasalazine)? **ACTION REQUIRED:** If Yes, please attach documentation of clinical reason to avoid therapy.

- Yes, *Continue to 44*
- No, *Continue to 44*

36. Please indicate the contraindication methotrexate or leflunomide.

- Clinical diagnosis of alcohol use disorder, alcoholic liver disease, or other chronic liver disease, *Continue to 44*
- Drug interaction, *Continue to 44*
- Risk of treatment-related toxicity, *Continue to 44*
- Pregnancy or currently planning pregnancy, *Continue to 44*
- Breastfeeding, *Continue to 44*
- Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension), *Continue to 44*
- Hypersensitivity, *Continue to 44*
- History of intolerance or adverse event, *Continue to 44*
- Other, please specify. _____, *Continue to 44*

37. Has the patient been diagnosed with moderately to severely active Crohn's disease (CD)?

- Yes, *Continue to 38*
- No, *Continue to 38*

38. Is the patient an adult (18 years of age or older)?

- Yes, *Continue to 39*
- No, *Continue to 39*

39. Is the requested drug being prescribed by or in consultation with a gastroenterologist?

- Yes, *Continue to 40*
- No, *Continue to 40*

40. Which of the following applies to this request for the requested drug?

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org.**



- Initiation of the intravenous (IV) loading dose, *Continue to 44*
- Initiation of the subcutaneous (SQ) maintenance dose, *Continue to 44*
- Continuation of the subcutaneous (SQ) maintenance dose, *Continue to 41*

41. Has the patient achieved or maintained remission? **ACTION REQUIRED:** If Yes, please attach chart notes or medical record documentation of remission.

- Yes, *Continue to 44*
- No, *Continue to 42*

42. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

- Yes, *Continue to 43*
- No, *Continue to 43*

43. Which of the following has the patient experienced improvement in from baseline? **ACTION REQUIRED:** Please attach chart notes or medical record documentation supporting positive clinical response.

- Abdominal pain or tenderness **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Diarrhea **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Body weight **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Abdominal mass **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Hematocrit **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score) **ACTION REQUIRED:** *Submit supporting documentation, Continue to 44*
- None of the above, *Continue to 44*

44. What is the diagnosis?

- Plaque Psoriasis, *Continue to 45*
- Psoriatic arthritis WITH co-existent plaque psoriasis, *Continue to 45*
- Psoriatic arthritis, *Continue to 45*
- Crohn's disease, *Continue to 50*

45. Is the patient currently receiving the requested drug?

- Yes, *Continue to 46*
- No, *Continue to 48*

46. Does the prescribed dose exceed 150 mg?

- Yes, *Continue to 47*
- No, *Continue to 47*

47. Is the prescribed frequency for the maintenance dose more frequent than one dose every 12 weeks?

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org**



- Yes, *No Further Questions*
- No, *No Further Questions*

48. Does the prescribed dose exceed a loading dose of 150 mg at weeks 0 and 4, and a maintenance dose of 150 mg thereafter?

- Yes, *Continue to 49*
- No, *Continue to 49*

49. Is the prescribed frequency for the maintenance dose more frequent than one dose every 12 weeks?

- Yes, *No Further Questions*
- No, *No Further Questions*

50. Which of the following applies to this request for the requested drug?

- Initiation of the intravenous (IV) loading dose, *Continue to 51*
- Initiation of the subcutaneous (SQ) maintenance dose, *Continue to 53*
- Continuation of the subcutaneous (SQ) maintenance dose, *Continue to 53*

51. Does the prescribed dose exceed a loading dose of 600 mg at weeks 0, 4, and 8, and a maintenance dose of 360 mg at week 12 and thereafter?

- Yes, *Continue to 52*
- No, *Continue to 52*

52. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks?

- Yes, *No Further Questions*
- No, *No Further Questions*

53. Does the prescribed dose exceed 360 mg?

- Yes, *Continue to 54*
- No, *Continue to 54*

54. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks?

- Yes, *No Further Questions*
- No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHCPP Skyrizi SGM 3047-A – 01/2024.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org.**